Press "Enter" to skip to content

AstraZeneca invests in Imperial’s self-amplifying RNA technology with eye on future drugs

VaxEquity, a startup founded by Imperial vaccinologist Robin Shattock, could receive up to $195 million if certain milestones are met, in addition to royalties on approved drugs and equity investment from AstraZeneca and life sciences investor Morningside Ventures.

Original source: https://health.economictimes.indiatimes.com/news/pharma/86451023?utm_source=RSS&utm_medium=ETRSS